EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL

Isabel Redondo  1     Brian Feagan  2     Remo Panaccione  3     Christian Selinger  4     Trevor Lissoos  5     Vipin Arora  6     Milan Lukas     Katsuyoshi Matsuoka     Toshifumi Hibi    
1 Eli Lilly Portugal, Produtos FarmacĂȘuticos, Lda.,Lisbon,Portugal
2 Robarts Clinical Trials Inc,London,Canada
3 University of Calgary, Inflammatory Bowel Disease Center,Calgary,Canada
4 Leeds Teaching Hospitals NHS Trust,Leeds,United Kingdom
5 Eli Lilly and Company,Indianapolis, Indiana,United States
6 Eli Lilly and Company,Indianapolis, In

Session
IBD (Posters)

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing